гемофилия Bрекомбинантный препарат фактора IXИннонафакторОктанайн Фпрофилактическое лечениеэффективностьбезопасностьhemophilia Brecombinant factor IXInnonafactorOctanine Fprophylaxisefficacysafety1.Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., Key N.S., Kitchen S., Llinas A. et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19(1): e1-47.2.Franchini M., Frattini F., Crestani S., Sissa C., Bonfanti C. Treatment of hemophilia B: focus on recombinant factor IX. Biologics. 2013; 7: 33-8.3.Windyga J., Solano Trujillo M.H., Hafeman A.E. BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014; 5(5): 168-80.4.Gringeri A., Ewenstein B., Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014; 20(4): 459-63.5.Biss T.T., Chan A.K., Blanchette V.S., Iwenofu L.N., McLimont M., Carcao M.D. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia. 2008; 14(5): 923-30.6.Schulman S., Eelde A., Holmström M., Stâhlberg G., Odeberg J., Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost. 2008; 6(7): 1113-21.7.Lowe G.D., Ludlam C.A. Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost. 2008; 6(11): 1982-3.8.Tagariello G., Iorio A., Santagostino E., Morfini M., Bisson R., Innocenti M. et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood. 2009; 114(4): 779-84.9.White G.C. 2nd, Beebe A., Nielsen B. Recombinant factor IX. Thromb Haemost. 1997; 78(1): 261-5.10.Roth D.A., Kessler C.M., Pasi K.J., Rup B., Courter S.G., Tubridy K.L.; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001; 98(13): 3600-6.11.Poon M.C., Lillicrap D., Hensman C., Card R., Scully M.F. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost. 2002; 87(3): 431-5.12.Ewenstein B.M., Joist J.H., Shapiro A.D., Hofstra T.C., Leissinger C.A., Seremetis S.V. et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion. 2002; 42(2): 190-7.13.Shapiro A.D., Di Paola J., Cohen A., Pasi K.J., Heisel M.A., Blanchette V.S. et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005; 105(2): 518-25.14.Lambert T., Recht M., Valentino L.A., Powell J.S., Udata C., Sullivan S.T. et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007; 13(3): 233-43.15.Franchini M., Lippi G., Montagnana M., Targher G., Zaffanello M., Salvagno G.L. et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis. 2009; 20(4): 225-9.16.Astermark J., Santagostino E., Keith Hoots W. Clinical issues in inhibitors. Haemophilia. 2010; 16(Suppl. 5): 54-60.17.Monahan P.E., Liesner R., Sullivan S.T., Ramirez M.E., Kelly P., Roth D.A. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia. 2010; 16(3): 460-8.18.Franchini M., Mannucci P.M. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol. 2011; 72(4): 553-62.19.Recht M., Pollmann H., Tagliaferri A., Musso R., Janco R., Neuman W.R. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia. 2011; 17(3): 494-9.20.Berntorp E., Keeling D., Makris M., Tagliaferri A., Male C., Mauser-Bunschoten E.P. et al. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use. Haemophilia. 2012; 18(4): 503-9.21.Franchini M., Frattini F., Crestani S., Bonfanti C. Haemophilia B: current pharmacotherapy and future directions. Expert Opin Pharmacother. 2012; 13(14): 2053-63.22.Стандарт медицинской помощи больным с наследственным дефицитом фактора VIII, с наследственным дефицитом фактора IX, болезнью Виллебранда (Утвержден приказом Минздравсоцразвития РФ от 14.11.07 № 705). Режим доступа: http://rudoctor.net/medicine2009/bz-sw/med-rmgug/index.htm.23.Тарасова И.С. Новые возможности профилактики осложнений гемофилии у детей и взрослых (итоги совещания экспертов, Москва, 30 августа 2010 г.). Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2010; 9(3): 41-8.24.Зоренко В.Ю., Мишин Г.В., Северова Т.В., Шустер А.М., Кудлай Д.А., Лукьянов С.В. и др. Фармакокинетические свойства, безопасность и переносимость препарата Иннонафактор (результаты I фазы клинического исследования у больных с тяжелой и среднетяжелой формой гемофилии B). Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2014; 13(4): 39-49.25.Протокол ведения больных. Гемофилия. Проблемы стандартизации в здравоохранении. 2006; 3: 18-74.26.Румянцев А.Г., Румянцев С.А., Чернов В.М. Гемофилия в практике врачей различных специальностей. М.: ГЭОТАР-Медиа; 2013.27.Kisker C.T., Eisberg A., Schwartz B.; Mononine Study Group. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia. 2003; 9(3): 279-84.28.Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia. 2011; 17(2): 179-84.29.Lissitchkov T., Matysiak M., Zavilska K., Laguna P., Gercheva L., Antonov A. et al. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B. Haemophilia. 2013; 19(5): 674-8.